Navigation Links
WuXi PharmaTech Announces Third-Quarter 2013 Results
Date:11/12/2013

ent liabilities:Short-term and current portion of long-term debt49,406

59,089Accounts payable30,763

21,808Accrued expenses27,220

27,411Deferred revenue22,527

17,052Advanced subsidies11,435

9,265Other taxes payable7

1,581Other current liabilities14,128

11,215Total current liabilities155,486

147,421Non-current liabilities:Long-term debt, excluding current portion5,534

5,697Advanced subsidies1,902

2,663Long-term payables-

732Other non-current liabilities7,149

7,799Total non-current liabilities14,585

16,891Total liabilities170,071

164,312Equity:Ordinary shares ($0.02 par value, 5,002,550,000 authorized,  568,513,338 and 569,653,210 issued and outstanding as of December 31, 2012, and September 30, 2013, respectively) 11,393

11,222Additional paid-in capital346,383

331,714Retained earnings270,315

188,604Accumulated other comprehensive income64,913

46,683Total equity693,004

578,223Total liabilities and equity863,075

742,535 WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In thousands of U.S. dollars, except ADS data and per ADS data)Three Months Ended
 September 30,Nine Months Ended
 September 30,20132012% Change20132012% ChangeNet revenues:Laboratory Services108,060

98,925

9.2%311,444

279,119

11.6%Manufacturing Services38,659

26,919

43.6%109,467

95,134

15.1%Total net revenues146,719

125,844

16.6%420,911

374,253

12.5%Cost of revenues:Laboratory Services(66,929)

(61,097)

9.5%(192,557)

(174,840)

10.1%Manufacturing Services(27,053)

(18,657)

45.0%(76,456)

(64,938)

17.7%Total cost of revenues(93,982)

(79,754)

17.8%(269,013)
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
2. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
3. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
4. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
5. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
7. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
8. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
11. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... MISSISSAUGA, Ontario, June 14, 2011 Theramed Corporation ... jetty™ at the 67th Clinical Meeting of the Society ... developed medical devices are to be used to advance ... Both medical device products have been approved for sale ...
... the 2011 Society of Gastroenterology Nurses and Associates (SGNA) ... PA) presented the results of a study evaluating the ... organic soils remaining in flexible endoscopes after cleaning. ... (Healthmark Industries Company, Inc., Fraser, Michigan) is to test ...
Cached Medicine Technology:Theramed Corporation to Launch Glenveigh Products, ebb™ and jetty™ at the Society of Obstetricians and Gynecologists of Canada 2Flexible Endoscope Manufacturer Determines Test Suitable for Evaluating Cleanliness of Flexible Endoscopes 2
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... Complimentary Continuing Medical Education Virtual Lecture and Podcast ... Clostridium difficile infection (CDI) is changing ... more severe and complicated disease. Furthermore, the epidemic ... number of states across the United States, and ...
... Corporation (NYSE: CVS ) today announced ... Officer and Chief Administrative Officer, will be making ... Institutional Investors Conference on March 10, 2009. Mr. ... a.m. EDT. (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )An ...
... Supplement Offers Promising Results for Tired Baby ... Ribose Company(TM)--has announced preliminary findings indicating that ... The results were presented at the Scripps ... and is a patented functional ingredient for ...
... Diabetes patients undergoing team-based care do not save ... than other patients, but they are healthier, according ... a substantial financial burden on patients, payers and ... and administration, Penn State, and lead author of ...
... new article appearing in the March 2009 issue of ... ) may lead to improvements in the efficacy of ... researchers discovered a new role for type I interferon, ... to stimulate an immune response against the bacterium known ...
... It might one day be used as an ingredient in ... Past studies have suggested that caffeine might offer some protection ... "We have found what we believe to be the mechanism ... lead researcher Dr. Paul Nghiem, an associate professor of dermatology ...
Cached Medicine News:Health News:Interview with GI Experts: Discussions in Clostridium difficile 2Health News:CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th 2Health News:Bioenergy Ribose Found to Improve Vitality, Aerobic Fitness and Mental Outlook 2Health News:Bioenergy Ribose Found to Improve Vitality, Aerobic Fitness and Mental Outlook 3Health News:Team-based diabetes care fetches more value for dollar 2Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3
... Control is a human ... provides the laboratory with ... for lipids analysis. It ... in levels optimized for ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek® Drug Free Serum can serve as a drug-free baseline for HPLC analysis or as a negative control....
Medicine Products: